<https://helda.helsinki.fi>

Protein profiling of nasopharyngeal aspirates of hospitalized and outpatients revealed cytokines associated with severe influenza A(H1N1)pdm09 virus infections: A pilot study

Fu, Yu

2016-10

Fu , Y , Gaelings , L , Jalovaara , P , Kakkola , L , Kinnunen , M T , Kallio-Kokko , H , Valkonen , M , Kantele , A & Kainov , D E 2016 , ' Protein profiling of nasopharyngeal aspirates of hospitalized and outpatients revealed cytokines associated with severe influenza A(H1N1)pdm09 virus infections: A pilot study ' , Cytokine , vol. 86 , pp. 10-14 . <https://doi.org/10.1016/j.cytokine.2016.07.003>

<http://hdl.handle.net/10138/225037>

<https://doi.org/10.1016/j.cyto.2016.07.003>

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Protein profiling of nasopharyngeal aspirates of hospitalized and outpatients revealed cytokines associated with severe influenza A(H1N1)pdm09 virus infections: A pilot study

Yu Fu^a, Lana Gaelings^a, Petri Jalovaara^a, Laura Kakkola^{a,b}, Mervi T. Kinnunen^a, Hannimari Kallio-Kokko^c, Miia Valkonen^d, Anu Kantele^{d,e}, Denis E. Kainov^{a,*}

^a The Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland

^b Department of Virology, University of Turku, Finland

^c Department of Virology and Immunology, University of Helsinki and Helsinki University Hospital, HUSLAB, Finland

^d Department of Medicine, University of Helsinki, Finland

^e Inflammation Center, Helsinki University Hospital, Finland

ARTICLE INFO

Article history:

Received 25 May 2016

Received in revised form 4 July 2016

Accepted 5 July 2016

Available online 18 July 2016

Keywords:

Influenza virus

Cytokine

Chemokine

Nasopharyngeal aspirate

ABSTRACT

Influenza A viruses (IAV) mutate rapidly and cause seasonal epidemics and occasional pandemics, which result in substantial number of patient visits to the doctors and even hospitalizations. We aimed here to identify inflammatory proteins, which levels correlated to clinical severity of the disease. For this we analysed 102 cytokines and growth factors in human nasopharyngeal aspirate (NPA) samples of 27 hospitalized and 27 outpatients diagnosed with influenza A(H1N1)pdm09 virus infection. We found that the relative levels of monocyte differentiation antigen CD14, lipocalin-2 (LCN2), C-C-motif chemokine 20 (CCL20), CD147, urokinase plasminogen activator surface receptor (uPAR), pro-epidermal growth factor (EGF), trefoil factor 3 (TFF3), and macrophage migration inhibitory factor (MIF) were significantly lower ($p < 0.008$), whereas levels of retinol-binding protein 4 (RBP4), C-X-C motif chemokine 5 (CXCL5), interleukin-8 (IL-8), complement factor D (CFD), adiponectin, and chitinase-3-like 1 (CHI3L1) were significantly higher ($p < 0.008$) in NPA samples of hospitalized than non-hospitalized patients. While changes in CD14, LCN2, CCL20, uPAR, EGF, MIF, CXCL5, IL-8, adiponectin and CHI3L1 levels have already been correlated with severity of IAV infection in mice and humans, our study is the first to describe association of CD147, RBP4, TFF3, and CFD with hospitalization of IAV-infected patients. Thus, we identified local innate immune profiles, which were associated with the clinical severity of influenza infections.

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

We are surrounded by an enormous number of microbes, and some of them are pathogenic. Our immune system tries to protect us from pathogenic microbes, yet, from time to time, some of them evade our immune mechanisms and cause symptoms, which may lead to hospitalization and even death [1]. This may happen when pathogens acquire specific mutations in their genomes enabling them to bypass our immune barriers. In addition, our genetics, underlying health conditions, life-style and environmental factors can also influence our immune system and contribute to the development of severe forms of infectious diseases [2].

* Corresponding author at: Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Tukholmankatu 8, Helsinki 00290, Finland.

E-mail address: denis.kainov@helsinki.fi (D.E. Kainov).

Human influenza A viruses receive much attention in public because these viruses cause annual epidemics across the globe and occasionally pandemics [3,4]. The most recent influenza pandemic and following seasonal epidemics were associated mainly with viruses of the influenza A(H1N1)pdm09 lineage [5]. Infections with these viruses are manifested as an acute respiratory disease characterized by a sudden onset of high fever, cough, headache, prostration, malaise, and inflammation of the upper respiratory tract. Acute symptoms and fever often persisted for 7–10 days, and in most cases, the infections were self-limited and led to spontaneous recovery. However, in a small proportion of patients, influenza A(H1N1)pdm09 infection resulted in hospitalizations and even death. Often these patients belonged to risk groups, such as the elderly (>65 years old), young children (<5 years old), pregnant women and immunocompromised individuals [3,4]. However, a substantial number of previously healthy young adults were also hospitalized [6–8].

Many different factors could be associated with hospital admission of patients infected with A(H1N1)pdm09 viruses. For example, mutations in the viral genome could enhance virus replication, change virus tropism and modulate human immune and antiviral responses [9,10]. Defects in the host genes could also lower antiviral and general immune responses [11–21]. Furthermore, a variety of underlying conditions (e.g., cardiac and respiratory diseases, immunosuppression, co-infections), abnormal life-style (smoking) and environmental factors (humidity, temperature) increase the risk of hospitalization [22,23].

Here we explored soluble proteins in NPA samples of patients with influenza A(H1N1)pdm09 infection and compared their levels between those admitted to hospital and those treated as outpatients (Finland, 2009–2014). We identified altogether 14 cytokines, which were associated with hospitalizations.

2. Materials and methods

All patients were treated anonymously and samples were encoded. For intensive care unit patients, consent for sample collection was received from relatives or from the patients afterwards. All nasopharyngeal aspirates (NPAs) samples had been sent to HUSLAB for influenza A(H1N1)pdm09 virus diagnosis. Sample collections which demanded direct patient contact and consent procedure were approved by the ethical review committee of the University of Helsinki Central Hospital, Finland (165/13/03/00/2011). All the ethical issues were handled in accordance with the national and EU regulations (Directive 95/46/EC). Other relevant ethical issues, such as good clinical practice and respect of the Finnish legislation and guidelines were applied. No dual use or misuse issues were concerned.

We obtained NPAs from 54 patients. Half of the patients were hospitalized (16 females, mean age = 59 years; 11 males, mean age = 56) and other half were treated as outpatients (11 females, mean age = 40; and 16 males, mean age = 47) during 2009–2014 in Finland. The decision of hospitalization was based on a clinical evaluation of the severity of the disease as judged by an internist in the emergency room. The assessment was carried out according to local practices: if the clinician evaluates that the patient could not manage at home, the patient was hospitalized. As for those attending intensive care unit, the principles of evaluation were consistent with the Infectious Diseases Society of America

guidelines on community-acquired pneumonia [24]. Patients for the present study were selected among outpatients, hospitalized patients in the ward or in the intensive care unit. All 54 patients were diagnosed with influenza A(H1N1)pdm09 infections diagnosed by qRT-PCR as described previously [25].

The relative levels of 102 cytokines, chemokines, and growth factors were determined using the Proteome Profiler Human XL Cytokine Array Kit (R&D Systems Inc., USA) according to the manufacturer's instructions. Importantly, this immunoassay was chosen because it includes several biomarkers (e.g., CD14, LCN2, CCL20, uPAR, EGF, MIF, CXCL5, IL-8, adiponectin and CHI3L1), which were previously associated with severe IAV infections [26–35]. The results were analysed using ImageJ software. The average signal values of the pair of duplicate spots of each analyte were calculated. The background signal of each film was determined by using the minimum averaged signal value detected on each film. Background signals were subtracted and quantile normalization was used to normalize the data by using Bioconductor's preprocessCore package [Bolstad BM. *preprocessCore: A collection of pre-processing functions. R package version 1.32.0*]. Gene set enrichment analysis was performed using freely available software (<http://software.broadinstitute.org/gsea/index.jsp>).

Cytokine profiling data was log2 transformed for linear modelling and empirical-Bayes-moderated t-tests using the LIMMA package [36]. To analyse the differences caused by the hospitalization, a linear model was fit to each cytokine/metabolite; the conditions of the volunteers, i.e. hospitalized or non-hospitalized were indicated in the design matrix for this fit. The Benjamini-Hochberg method was used to correct for multiple testing. The significant cytokines were determined at a Benjamini-131 Hochberg false discovery rate (FDR) controlled at 10%. The heatmaps for cytokines and metabolites were generated using the heatmap package [Raivo Kolde (2015). *heatmap: Pretty Heatmaps. R package version 1.0.8*.] based on log transformed profiling data and the clustering of analytes in the heatmap was generated using the complete clustering method on Euclidian distances.

3. Results

To find correlations between patient hospitalizations and NPA cytokine levels, we collected NPA samples from 54 Finnish patients diagnosed by RT-qPCR with A(H1N1)pdm09 influenza virus

Fig. 1. Profile of 14 cytokines differentially expressed in nasopharyngeal samples of 27 hospitalized and 27 outpatients diagnosed with influenza A(H1N1)pdm09 virus infection. A heatmap of 14 cytokines is shown. Rows represent cytokines. Columns represent samples. Each cell is coloured according to the average of log2-transformed profiling values. Complete-linkage hierarchical clustering based on Euclidian distances was used for clustering of cytokines.

Table 1

Proteins differentially up- or downregulated in NPA samples of hospitalized versus non-hospitalized patients with influenza A(H1N1)pdm09 virus infection.

Cytokine	Gene	Log2-transformed fold change	Adjusted p value
CD14	CD14	−1.7358431	7.26E−06
LCN2	LCN2	−0.944612	2.96E−04
CCL20	CCL20	−1.5743026	4.75E−04
CD147	BSG	−1.5598086	7.22E−04
uPAR	PLAUR	−0.882148	9.17E−04
EGF	EGF	−1.3042082	1.34E−03
RBP4	RBP4	1.7491274	1.43E−03
TFF3	TFF3	−0.6944493	1.76E−03
CXCL5	CXCL5	1.919249	3.64E−03
IL-8	IL8	1.3530835	5.38E−03
CFD	CFD	0.9796998	7.89E−03
Adiponectin	ADIPOQ	1.3518806	7.92E−03
CHI3L1	CHI3L1	1.7888313	7.92E−03
MIF	MIF	−0.8717891	8.06E−03

infection during 2009–2014. Twenty-seven of these patients were hospitalized and 27 treated as outpatients. We profiled 102 cytokines, chemokines, and growth factors in two groups of NPA samples using an immunoassay. We observed significant differences between the serum levels of 14 proteins of hospitalized cases versus non-hospitalized controls (Fig. 1; Table 1). In particular, the NPA levels of RBP4, CXCL5, IL-8, CFD, adiponectin, and CHI3L1 were elevated, whereas the levels of CD14, LCN2, CCL20, CD147, uPAR, EGF, TFF3, and MIF were decreased in hospitalized patients in comparison with non-hospitalized controls. Analysis of the genes which encode identified proteins revealed, that some of them are also implicated in immune response and chemotaxis and up- or down-regulated in pulpal tissue extracted from carious teeth, in cancer endometrium samples compared to the normal endometrium, in NMuMG cells (mammary epithelium) after stimulation with both TGFβ1 and WNT3A, and in vitro maturation of CD14+ monocytes into immature and mature dendritic cells (Table S1).

4. Discussion

IAVs infect epithelial cells, macrophages and dendritic cells of the respiratory tract. These cells represent the first line of defence against influenza virus infection. These cells mount innate immune responses through production of soluble mediators such as cytokines. When infected cells die by apoptosis or necrosis, they trigger inflammatory responses. The acute inflammatory response is also marked by the activation of pro-inflammatory cytokines or chemokines. These cytokines or chemokines lead to the recruitment of inflammatory cells. The expression of inflammatory, antiviral, and apoptotic genes can be accompanied by abundant immune cell infiltration and tissue damage. At the same time, regenerative processes and resolution of the damage are initiated. In most cases, the function can be completely restored by this reparative process. Severe inflammation usually leads to more serious pathological changes, such as diffuse alveolar damage, hyaline membrane formation, fibrin exudates, and fibrotic healing. These are signs of severe capillary damage, immunopathologic injury, and persistent organ dysfunction. Patients with these signs are usually hospitalized.

The events in severe disease lead to changes in levels of a variety of markers, which identification could potentially be exploited in clinical practise. In particular, the efficacy of treatment can be better evaluated. In this study we analysed levels of 102 soluble proteins in NPA samples of hospitalized and non-hospitalized

Finnish patients with influenza A(H1N1)pdm09 virus infections. We found that the levels of CD14, LPN2, CCL20, CD147, uPAR, EGF, TFF3, MIF were significantly lower, whereas those of RBP4, CXCL5, IL-8, CFD, adiponectin, and CHI3L1 were significantly higher in hospitalized patients. Interestingly, CD14, LCN2, CCL20, uPAR, EGF, MIF, CXCL5, IL-8, adiponectin and CHI3L1 have been already associated with an increased severity of influenza virus infections in mice and humans [26–35]. By contrast, the present study is the first to demonstrate that increased levels of CD147, RBP4, TFF3, and CFD are associated with hospitalization due to IAV.

CD147 is a member of the immunoglobulin superfamily, which plays fundamental role in intercellular recognition during various immunologic processes, as well as in cell differentiation and development [37]. In addition to its metalloproteinase-inducing ability, CD147 also regulates spermatogenesis, expression of the monocarboxylate transporter and the responsiveness of lymphocytes [38]. Moreover, CD147 was shown to be a receptor in erythrocyte invasion by most strains of the malaria parasite *Plasmodium falciparum* [39]. RBP4 belongs to the lipocalin family and is the specific carrier for retinol in the blood [40]. It delivers retinol from the liver stores to the peripheral tissues. A deficiency of retinol blocks secretion of the binding protein post translationally and results in defective delivery and supply to the epidermal cells. RBP4 has also been described as an adipokine that contributes to insulin resistance in obesity, type 2 diabetes and cardiovascular diseases [41]. In addition, it was shown that RBP4 associates with HIV-, HCV- and schistosomiasis-mediated disease progression, inflammation and mortality [42–44]. TFF3 is a member of the trefoil family. Its function is not defined, but it may protect the mucosa from injury, stabilize the mucus layer, and affect healing of the epithelium. It also plays a role in the immune response following infection with *Toxoplasma gondii* [45]. In addition, it downregulates IL-8 and IL-6 levels [46]. CFD is a serine protease secreted by adipocytes into the bloodstream. It is a component of the alternative complement pathway best known for its role in humoral suppression of infectious agents. Thus, CD147, RBP4, TFF3, and CFD play a role in immune responses to infection. These, and ten other identified proteins in respiratory samples, as well as their combinations (such as TFF3/IL-8 pair), might be exploited for evaluation of efficacy of treatment.

It should be noted that differences in concentrations of the 14 NPA proteins could be not solely due to IAV infection but, in part to secondary bacterial infections [47]. In particular, CD14, LCN2, CCL20, MIF, and CHI3L1 have been shown to play a role in bacterial infections [48–52]. Moreover, the differences could be associated with other microbe and host signatures, such as genetics, underlying health conditions, life-style and environmental factors. Nevertheless, the identified proteins can reflect the risk for more severe form of disease in IAV infection. In summary, we identified local nasopharyngeal innate immune profiles, which were correlated with patient hospitalization due to influenza A virus infection.

Acknowledgments

This work was supported by the University of Helsinki three-year research project grant (465/51/2014) and Jane and Aatos Erkko foundation.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.cyto.2016.07.003>.

References

- [1] C. Hermann, Review: variability of host-pathogen interaction, *J. Endotoxin Res.* 13 (2007) 199–218.
- [2] M. Sironi, R. Cagliani, D. Forni, M. Clerici, Evolutionary insights into host-pathogen interactions from mammalian sequence data, *Nat. Rev. Genet.* 16 (2015) 224–236.
- [3] Who, Influenza (seasonal), Fact sheet n°211, 2014, <<http://www.who.int/mediacentre/factsheets/fs211/en/>>.
- [4] Pandemic flu history, 2014, <<http://www.flu.gov/pandemic/history/>>.
- [5] Global alert and response (gar), Pandemic and epidemic diseases, Pandemic (H1N1) 2009, 2014, <<http://www.who.int/csr/disease/swineflu/en/>>.
- [6] Fluvium, Laboratory-confirmed influenza hospitalizations, 2015, <<http://gis.cdc.gov/GRASP/Fluview/FluHospRateshtml>>.
- [7] Fluview, Mortality surveillance data from the national center for health statistics, 2015, <<http://www.cdc.gov/flu/weekly/nchshtml>>.
- [8] M.D. Van Kerkhove, S. Hirve, A. Koukounari, A.W. MountsGroup HNpsw, Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries, *Influenza Other Respir. Viruses* 2013 (7) (2009) 872–886.
- [9] E.A. Goka, P.J. Vally, K.J. Mutton, P.E. Klapper, Mutations associated with severity of the pandemic influenza A(H1N1)pdm09 in humans: a systematic review and meta-analysis of epidemiological evidence, *Arch. Virol.* 159 (2014) 3167–3183.
- [10] P. Mishel, T. Ojala, C. Benner, T. Lakspere, D. Bychkov, P. Jalovaara, L. Kakkola, H. Kallio-Kokko, A. Kantele, M. Kankainen, N. Ikonen, S. Ripatti, I. Julkunen, D.E. Kainov, Comparative analysis of whole-genome sequences of influenza A (H1N1)pdm09 viruses isolated from hospitalized and nonhospitalized patients identifies missense mutations that might be associated with patient hospital admissions in Finland during 2009 to 2014, *Genome Announc.* 2015 (2009) 3.
- [11] A. Maestri, V.A. Sortica, L. Tovo-Rodrigues, M.C. Santos, L. Barbagelata, M.R. Moraes, W. Alencar de Mello, L. Gusmao, R.C. Sousa, S. Emanuel Batista Dos Santos, Sialpha2–3galbeta1- receptor genetic variants are associated with influenza A(H1N1)pdm09 severity, *PLoS One* 10 (2015) e0139681.
- [12] K. Garcia-Etxebarria, M.A. Bracho, J.C. Galan, T. Pumarola, J. Castilla, R. Ortiz de Lejarazu, M. Rodriguez-Dominguez, I. Quintela, N. Bonet, M. Garcia-Garcera, A. Dominguez, F. Gonzalez-Candelas, F. CalafellCIBERESP Cases and Controls in Pandemic Influenza Working Group, No major host genetic risk factor contributed to A(H1N1)2009 influenza severity, *PLoS One* 10 (2015) e0135983.
- [13] Z. Cheng, J. Zhou, K.K. To, H. Chu, C. Li, D. Wang, D. Yang, S. Zheng, K. Hao, Y. Bosse, M. Obeidat, C.A. Brandsma, Y.Q. Song, Y. Chen, B.J. Zheng, L. Li, K.Y. Yuen, Identification of TMPRSS2 as a susceptibility gene for severe 2009 pandemic A (H1N1) influenza and A(H7N9) influenza, *J. Infect. Dis.* 212 (2015) 1214–1221.
- [14] E. Herrera-Ramos, M. Lopez-Rodriguez, J.J. Ruiz-Hernandez, J.P. Horcajada, L. Borderias, E. Lerma, J. Blanquer, M.C. Perez-Gonzalez, M.I. Garcia-Laorden, Y. Florido, V. Mas-Bosch, M. Montero, J.M. Ferrer, L. Sorli, C. Vilaplana, O. Rajas, M. Briones, J. Aspa, E. Lopez-Granados, J. Sole-Violan, F.R. de Castro, C. Rodriguez-Gallego, Surfactant protein a genetic variants associate with severe respiratory insufficiency in pandemic influenza a virus infection, *Crit Care* 18 (2014) R127.
- [15] K.K. To, J. Zhou, Y.Q. Song, I.F. Hung, W.C. Ip, Z.S. Cheng, A.S. Chan, R.Y. Kao, A.K. Wu, S. Chau, W.K. Luk, M.S. Ip, K.H. Chan, K.Y. Yuen, Surfactant protein b gene polymorphism is associated with severe influenza, *Chest* 145 (2014) 1237–1243.
- [16] Y.H. Zhang, Y. Zhao, N. Li, Y.C. Peng, E. Giannoulou, R.H. Jin, H.P. Yan, H. Wu, J. H. Liu, N. Liu, D.Y. Wang, Y.L. Shu, L.P. Ho, P. Kellam, A. McMichael, T. Dong, Interferon-induced transmembrane protein-3 genetic variant rs12252-c is associated with severe influenza in Chinese individuals, *Nat. Commun.* 4 (2013) 1418.
- [17] J. Zhou, K.K. To, H. Dong, Z.S. Cheng, C.C. Lau, V.K. Poon, Y.H. Fan, Y.Q. Song, H. Tse, K.H. Chan, B.J. Zheng, G.P. Zhao, K.Y. Yuen, A functional variation in cd55 increases the severity of 2009 pandemic H1N1 influenza a virus infection, *J. Infect. Dis.* 206 (2012) 495–503.
- [18] A.R. Everitt, S. Clare, T. Pertel, S.P. John, R.S. Wash, S.E. Smith, C.R. Chin, E.M. Feeley, J.S. Sims, D.J. Adams, H.M. Wise, L. Kane, D. Goulding, P. Digard, V. Anttila, J.K. Baillie, T.S. Walsh, D.A. Hume, A. Palotie, Y. Xue, V. Colonna, C. Tyler-Smith, J. Dunning, S.B. Gordon, I.I. Gen, M. Investigators, R.L. Smyth, P.J. Openshaw, G. Dougan, A.L. Brass, P. Kellam, Ifitm3 restricts the morbidity and mortality associated with influenza, *Nature* 484 (2012) 519–523.
- [19] A. Antonopoulou, F. Baziaka, T. Tsaganos, M. Raftogiannis, P. Koutoukas, A. Spyridaki, M. Mouktaroudi, A. Kotsaki, A. Savva, M. Georgitsi, E.J. Giamarellos-Bourboulis, Role of tumor necrosis factor gene single nucleotide polymorphisms in the natural course of 2009 influenza a H1N1 virus infection, *Int. J. Infect. Dis.* 16 (2012) e204–208.
- [20] J. Zuniga, I. Buendia-Roldan, Y. Zhao, L. Jimenez, D. Torres, J. Romo, G. Ramirez, A. Cruz, G. Vargas-Alarcon, C.C. Sheu, F. Chen, L. Su, A.M. Tager, A. Pardo, M. Selman, D.C. Christians, Genetic variants associated with severe pneumonia in A/H1N1 influenza infection, *Eur. Respir. J.* 39 (2012) 604–610.
- [21] C.Y. Li, Q. Yu, Z.Q. Ye, Y. Sun, Q. He, X.M. Li, W. Zhang, J. Luo, X. Gu, X. Zheng, L. Wei, A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir, *Cell Res.* 17 (2007) 357–362.
- [22] A.C. Arcanjo, G. Mazzocco, S.F. de Oliveira, D. Plewczynski, J.P. Radomski, Role of the host genetic variability in the influenza a virus susceptibility, *Acta Biochim. Pol.* 61 (2014) 403–419.
- [23] P. Horby, N.Y. Nguyen, S.J. Dunstan, J.K. Baillie, The role of host genetics in susceptibility to influenza: a systematic review, *PLoS One* 7 (2012) e33180.
- [24] L.A. Mandell, R.G. Wunderink, A. Anzueto, J.G. Bartlett, G.D. Campbell, N.C. Dean, S.F. Dowell, T.M. File Jr., D.M. Musher, M.S. Niederman, A. Torres, C.G. Whitney, Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults, *Clin. Infect. Dis.* 44 (Suppl 2) (2007) S27–S72.
- [25] E. Ronkko, N. Ikonen, M. Kontio, M. Haanpaa, H. Kallio-Kokko, L. Mannonen, M. Lappalainen, I. Julkunen, T. Ziegler, Validation and diagnostic application of ns and ha gene-specific real-time reverse transcription-pcr assays for detection of 2009 pandemic influenza A (H1N1) viruses in clinical specimens, *J. Clin. Microbiol.* 49 (2011) 2009–2011.
- [26] M.T. Rondina, K. Tatsumi, J.A. Bastarache, N. Mackman, Microvesicle tissue factor activity and interleukin-8 levels are associated with mortality in patients with influenza A/H1N1 infection, *Crit Care Med.* (2016).
- [27] M. Ramos, Y. Lao, C. Eguiluz, M. Del Val, I. Martinez, Urokinase receptor-deficient mice mount an innate immune response to and clarify respiratory viruses as efficiently as wild-type mice, *Virulence* 6 (2015) 710–715.
- [28] J. Guo, F. Huang, J. Liu, Y. Chen, W. Wang, B. Cao, Z. Zou, S. Liu, J. Pan, C. Bao, M. Zeng, H. Xiao, H. Gao, S. Yang, Y. Zhao, Q. Liu, H. Zhou, J. Zhu, X. Liu, W. Liang, Y. Yang, S. Zheng, J. Yang, H. Diao, K. Su, L. Shao, H. Cao, Y. Wu, M. Zhao, S. Tan, H. Li, X. Xu, C. Wang, J. Zhang, L. Wang, J. Wang, J. Xu, D. Li, N. Zhong, X. Cao, G.F. Gao, L. Li, C. Jiang, The serum profile of hypercytokinemia factors identified in h7n9-infected patients can predict fatal outcomes, *Sci. Rep.* 5 (2015) 10942.
- [29] K.M. Robinson, K.J. McHugh, S. Mandalapu, M.E. Clay, B. Lee, E.V. Scheller, R.I. Enelow, Y.R. Chan, J.K. Kolls, J.F. Alcorn, Influenza a virus exacerbates staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production, *J. Infect. Dis.* 209 (2014) 865–875.
- [30] A. Bradley-Stewart, L. Jolly, W. Adamson, R. Gunson, C. Frew-Gillespie, K. Templeton, C. Aitken, W. Carman, S. Cameron, C. McSharry, Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09, *J. Clin. Virol.* 58 (2013) 100–107.
- [31] K.A. Shirey, W. Lai, A.J. Scott, M. Lipsky, P. Mistry, L.M. Pletneva, C.L. Karp, J. McAlees, T.L. Gioannini, J. Weiss, W.H. Chen, R.K. Ernst, D.P. Rossignol, F. Gusovsky, J.C. Blanco, S.N. Vogel, The tlr4 antagonist eritoran protects mice from lethal influenza infection, *Nature* 497 (2013) 498–502.
- [32] A. Duemmler, A.R. Montes-Vizuet, J.S. Cruz, L.M. Teran, CXCL5 en el tracto respiratorio superior de niños con influenza A, *Rev. Med. Inst. Mex. Seguro. Soc.* 48 (2010) 393–398.
- [33] C. Tsatsanis, A.N. Margioris, D.P. Kontoyiannis, Association between H1N1 infection severity and obesity-adiponectin as a potential etiologic factor, *J. Infect. Dis.* 202 (2010) 459–460.
- [34] C. Pauligk, M. Nain, N. Reiling, D. Gerns, A. Kaufmann, CD14 is required for influenza a virus-induced cytokine and chemokine production, *Immunobiology* 209 (2004) 3–10.
- [35] M.D. Wareing, A.B. Lyon, B. Lu, C. Gerard, S.R. Sarawar, Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza a virus infection in mice, *J. Leukoc. Biol.* 76 (2004) 886–895.
- [36] J.M. Wettenhall, G.K. Smyth, Limma: a graphical user interface for linear modeling of microarray data, *Bioinformatics* 20 (2004) 3705–3706.
- [37] T. Miyauchi, T. Kanekura, A. Yamaoka, M. Ozawa, S. Miyazawa, T. Muramatsu, Basigin, a new, broadly distributed member of the immunoglobulin superfamily, has strong homology with both the immunoglobulin v domain and the beta-chain of major histocompatibility complex class ii antigen, *J. Biochem.* 107 (1990) 316–323.
- [38] V. Yurchenko, S. Constant, M. Bukrinsky, Dealing with the family: CD147 interactions with cyclophilins, *Immunology* 117 (2006) 301–309.
- [39] C. Crossier, L.Y. Bustamante, S.J. Bartholdson, A.K. Bei, M. Theron, M. Uchikawa, S. Mboup, O. Ndir, D.P. Kwiatkowski, M.T. Duraisingh, J.C. Rayner, G.J. Wright, Basigin is a receptor essential for erythrocyte invasion by *Plasmodium falciparum*, *Nature* 480 (2011) 534–537.
- [40] N. Noy, Vitamin a in regulation of insulin responsiveness: mini review, *Proc. Nutr. Soc.* 75 (2016) 212–215.
- [41] M. Fasshauer, M. Blüher, Adipokines in health and disease, *Trends Pharmacol. Sci.* 36 (2015) 461–470.
- [42] S.R. Kotze, R. Zinyama-Gutsire, P. Kallestrup, C.S. Benn, E. Gomo, J. Gerstoft, G. van Dam, O.H. Mortensen, H. Ullum, C. Erikstrup, HIV and schistosomiasis in rural Zimbabwe: the association of retinol-binding protein with disease progression, inflammation and mortality, *Int. J. Infect. Dis.: IJID: Official Publ. Int. Soc. Infect. Dis.* 33 (2015) 159–164.
- [43] K. Gouthamchandra, A. Kumar, S. Shwetha, A. Mukherjee, M. Chandra, B. Ravishankar, M.N. Khaja, P.C. Sadhukhan, S. Das, Serum proteomics of hepatitis c virus infection reveals retinol-binding protein 4 as a novel regulator, *J. Gen. Virol.* 95 (2014) 1654–1667.
- [44] J.F. Huang, C.Y. Dai, M.L. Yu, S.J. Shin, M.Y. Hsieh, C.F. Huang, L.P. Lee, K.D. Lin, Z. Y. Lin, S.C. Chen, M.Y. Hsieh, L.Y. Wang, W.Y. Chang, W.L. Chuang, Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis c, *J. Hepatol.* 50 (2009) 471–478.
- [45] T. Fu, E.B. Znalesniak, T. Kalinski, L. Mohle, A. Biswas, F. Salm, I.R. Dunay, W. Hoffmann, Tff peptides play a role in the immune response following oral infection of mice with *Toxoplasma gondii*, *Eur. J. Microbiol. Immunol. (Bp)* 5 (2015) 221–231.
- [46] G.J. Barrera, G. Sanchez, J.E. Gonzalez, Trefoil factor 3 isolated from human breast milk downregulates cytokines (IL8 and IL6) and promotes human beta defensin (hBD2 and hBD4) expression in intestinal epithelial cells ht-29, *Bosn. J. Basic Med. Sci.* 12 (2012) 256–264.

- [47] G.A. Damasio, L.A. Pereira, S.D. Moreira, C.N. Duarte dos Santos, L.M. Dalla-Costa, S.M. Raboni, Does virus-bacteria coinfection increase the clinical severity of acute respiratory infection?, *J. Med. Virol.* 87 (2015) 1456–1461.
- [48] S. Bohr, S.J. Patel, R. Vasko, K. Shen, A. Golberg, F. Berthiaume, M.L. Yarmush, The role of chi3l1 (chitinase-3-like-1) in the pathogenesis of infections in burns in a mouse model, *PLoS One* 10 (2015) e0140440.
- [49] C. Chenevier-Gobeaux, D. Borderie, N. Weiss, T. Mallet-Coste, Y.E. Claessens, Presepsin (sCD14-ST), an innate immune response marker in sepsis, *Clin. Chim. Acta* 450 (2015) 97–103.
- [50] W. Guesdon, G. Auray, T. Pezier, F.I. Bussiere, F. Drouet, Y. Le Vern, M. Marquis, L. Potiron, S. Rabot, A. Bruneau, C. Werts, F. Laurent, S. Lacroix-Lamande, CCL20 displays antimicrobial activity against *cryptosporidium parvum*, but its expression is reduced during infection in the intestine of neonatal mice, *J. Infect. Dis.* 212 (2015) 1332–1340.
- [51] A.M. Dittrich, H.A. Meyer, E. Hamelmann, The role of lipocalins in airway disease, *Clin. Exp. Allergy* 43 (2013) 503–511.
- [52] T. Calandra, T. Roger, Macrophage migration inhibitory factor: a regulator of innate immunity, *Nat. Rev. Immunol.* 3 (2003) 791–800.